How Real-World Data Is Reshaping the NSCLC Patient JourneyNews DeskMarch 27, 20260 Most pharma companies want to ensure their drugs are effective for the greatest portion of the patient populations they are…
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating DrugsNews DeskMarch 26, 20260 Hunter syndrome patients can manage the disorder with a drug that addresses disease symptoms throughout the body except the brain…
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer DrugNews DeskMarch 25, 20260 Merck is picking up a big new piece for its cancer drug pipeline with a $6.7 billion deal to acquire…
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro AcquisitionNews DeskMarch 24, 20260 Gilead Sciences identified inflammation as an area for pipeline and revenue growth and the company is expanding its prospects through…
Why Novartis Is Paying $2B for a Cancer Drug That Hits the Same Target as One of Its Own ProductsNews DeskMarch 23, 20260 Breast cancers driven by a particular genetic signature can already be treated by a particular class of targeted therapies, but…